Clinical Trial Details

Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the correction or maintenance treatment of anemia in subjects with incident Dialysis Dependent Chronic kidney disease (DD-CKD) (INNO2VATE – CORRECTION/CONVERSION) (Protocol # AKB-6548-CI-0016)

This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of vadadustat versus darbepoetin alfa for the correction or maintenance treatment in subjects with anemia secondary to CKD who have recently initiated dialysis treatment for end-stage renal disease

Learn More

Principal Investigator(s)


Maryanne Ducey


Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.